Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Immune-mediated ECM depletion improves tumour perfusion and payload delivery.

Yeow YL, Kotamraju VR, Wang X, Chopra M, Azme N, Wu J, Schoep TD, Delaney DS, Feindel K, Li J, Kennedy KM, Allen WM, Kennedy BF, Larma I, Sampson DD, Mahakian LM, Fite BZ, Zhang H, Friman T, Mann AP, Aziz FA, Kumarasinghe MP, Johansson M, Ee HC, Yeoh G, Mou L, Ferrara KW, Billiran H, Ganss R, Ruoslahti E, Hamzah J.

EMBO Mol Med. 2019 Dec;11(12):e10923. doi: 10.15252/emmm.201910923. Epub 2019 Nov 11.

2.

Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery.

Lingasamy P, Tobi A, Haugas M, Hunt H, Paiste P, Asser T, Rätsep T, Kotamraju VR, Bjerkvig R, Teesalu T.

Biomaterials. 2019 Oct;219:119373. doi: 10.1016/j.biomaterials.2019.119373. Epub 2019 Jul 19.

3.

Peptide-guided nanoparticles for glioblastoma targeting.

Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, Friedmann-Morvinski D, Teesalu T.

J Control Release. 2019 Aug 28;308:109-118. doi: 10.1016/j.jconrel.2019.06.018. Epub 2019 Jun 27.

PMID:
31255690
4.

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.

He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R.

J Pathol. 2018 Jun;245(2):209-221. doi: 10.1002/path.5080. Epub 2018 Apr 20.

5.

Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Wonder E, Simón-Gracia L, Scodeller P, Majzoub RN, Kotamraju VR, Ewert KK, Teesalu T, Safinya CR.

Biomaterials. 2018 Jun;166:52-63. doi: 10.1016/j.biomaterials.2018.02.052. Epub 2018 Mar 2.

6.

Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.

Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, De Palma M, Ruoslahti E, Teesalu T.

Sci Rep. 2017 Nov 7;7(1):14655. doi: 10.1038/s41598-017-14709-x.

7.

Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy.

Cureton N, Korotkova I, Baker B, Greenwood S, Wareing M, Kotamraju VR, Teesalu T, Cellesi F, Tirelli N, Ruoslahti E, Aplin JD, Harris LK.

Theranostics. 2017 Aug 29;7(15):3715-3731. doi: 10.7150/thno.19678. eCollection 2017.

8.

Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Sharma S, Mann AP, Mölder T, Kotamraju VR, Mattrey R, Teesalu T, Ruoslahti E.

J Control Release. 2017 Dec 28;268:49-56. doi: 10.1016/j.jconrel.2017.10.006. Epub 2017 Oct 13.

9.

Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.

Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.

J Control Release. 2017 Aug 28;260:142-153. doi: 10.1016/j.jconrel.2017.06.005. Epub 2017 Jun 8.

10.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

11.

Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.

Sharma S, Kotamraju VR, Mölder T, Tobi A, Teesalu T, Ruoslahti E.

Nano Lett. 2017 Mar 8;17(3):1356-1364. doi: 10.1021/acs.nanolett.6b03815. Epub 2017 Feb 17.

12.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T.

Biomaterials. 2016 Oct;104:247-57. doi: 10.1016/j.biomaterials.2016.07.023. Epub 2016 Jul 20.

13.

Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque.

She ZG, Hamzah J, Kotamraju VR, Pang HB, Jansen S, Ruoslahti E.

J Control Release. 2016 Sep 28;238:212-220. doi: 10.1016/j.jconrel.2016.07.020. Epub 2016 Jul 15.

PMID:
27423327
14.

Tumor-homing peptides as tools for targeted delivery of payloads to the placenta.

King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, Agemy L, Teesalu T, Glazier JD, Cellesi F, Tirelli N, Aplin JD, Ruoslahti E, Harris LK.

Sci Adv. 2016 May 6;2(5):e1600349. doi: 10.1126/sciadv.1600349. eCollection 2016 May.

15.

A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries.

Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She ZG, Kotamraju VR, Ranscht B, Krajewski S, Teesalu T, Bhatia S, Sailor MJ, Ruoslahti E.

Nat Commun. 2016 Jun 28;7:11980. doi: 10.1038/ncomms11980.

16.

Rab11 and Lysotracker Markers Reveal Correlation between Endosomal Pathways and Transfection Efficiency of Surface-Functionalized Cationic Liposome-DNA Nanoparticles.

Majzoub RN, Wonder E, Ewert KK, Kotamraju VR, Teesalu T, Safinya CR.

J Phys Chem B. 2016 Jul 7;120(26):6439-53. doi: 10.1021/acs.jpcb.6b04441. Epub 2016 Jun 3.

17.

Urokinase-controlled tumor penetrating peptide.

Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T.

J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

18.

New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.

Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, Ruoslahti E, Teesalu T.

Chembiochem. 2016 Apr 1;17(7):570-5. doi: 10.1002/cbic.201500564. Epub 2016 Feb 19.

19.

Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes.

Ewert KK, Kotamraju VR, Majzoub RN, Steffes VM, Wonder EA, Teesalu T, Ruoslahti E, Safinya CR.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1618-1623. doi: 10.1016/j.bmcl.2016.01.079. Epub 2016 Feb 4.

20.

Targeted silver nanoparticles for ratiometric cell phenotyping.

Willmore AM, Simón-Gracia L, Toome K, Paiste P, Kotamraju VR, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2016 Apr 28;8(17):9096-101. doi: 10.1039/c5nr07928d.

21.

Gated Luminescence Imaging of Silicon Nanoparticles.

Joo J, Liu X, Kotamraju VR, Ruoslahti E, Nam Y, Sailor MJ.

ACS Nano. 2015 Jun 23;9(6):6233-41. doi: 10.1021/acsnano.5b01594. Epub 2015 Jun 9.

22.

Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.

Hamilton AM, Aidoudi-Ahmed S, Sharma S, Kotamraju VR, Foster PJ, Sugahara KN, Ruoslahti E, Rutt BK.

J Mol Med (Berl). 2015 Sep;93(9):991-1001. doi: 10.1007/s00109-015-1279-x. Epub 2015 Apr 14.

23.

Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment.

Kotamraju VR, Sharma S, Kolhar P, Agemy L, Pavlovich J, Ruoslahti E.

Breast Cancer (Auckl). 2016 Jun 27;9(Suppl 2):79-87. doi: 10.4137/BCBCR.S29426. eCollection 2015.

24.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

25.

Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.

Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F.

Mol Pharm. 2014 Dec 1;11(12):4374-84. doi: 10.1021/mp500456k. Epub 2014 Nov 4.

26.

Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin.

She ZG, Liu X, Kotamraju VR, Ruoslahti E.

ACS Nano. 2014 Oct 28;8(10):10139-49. doi: 10.1021/nn502947b. Epub 2014 Oct 7.

PMID:
25270510
27.

Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Braun GB, Friman T, Pang HB, Pallaoro A, Hurtado de Mendoza T, Willmore AM, Kotamraju VR, Mann AP, She ZG, Sugahara KN, Reich NO, Teesalu T, Ruoslahti E.

Nat Mater. 2014 Sep;13(9):904-11. doi: 10.1038/nmat3982. Epub 2014 Jun 8.

28.

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity.

Pang HB, Braun GB, She ZG, Kotamraju VR, Sugahara KN, Teesalu T, Ruoslahti E.

J Control Release. 2014 Feb 10;175:48-53. doi: 10.1016/j.jconrel.2013.12.006. Epub 2013 Dec 15.

29.

Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S.

Cancer Res. 2013 Dec 1;73(23):6987-97. doi: 10.1158/0008-5472.CAN-12-4477. Epub 2013 Oct 11.

30.

Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E.

Mol Ther. 2013 Dec;21(12):2195-204. doi: 10.1038/mt.2013.191. Epub 2013 Aug 20. Erratum in: Mol Ther. 2014 Nov;22(11):2013.

31.

Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing.

Zanuy D, Sayago FJ, Revilla-López G, Ballano G, Agemy L, Kotamraju VR, Jiménez AI, Cativiela C, Nussinov R, Sawvel AM, Stucky G, Ruoslahti E, Alemán C.

J Comput Aided Mol Des. 2013 Jan;27(1):31-43. doi: 10.1007/s10822-012-9623-5. Epub 2012 Dec 14.

PMID:
23239171
32.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

33.

Transtumoral targeting enabled by a novel neuropilin-binding peptide.

Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E.

Oncogene. 2012 Aug 16;31(33):3754-63. doi: 10.1038/onc.2011.537. Epub 2011 Dec 19.

PMID:
22179825
34.

X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles.

Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi NC, Ruoslahti E, Stupack D, Sailor MJ.

Angew Chem Int Ed Engl. 2011 Dec 16;50(51):12308-11. doi: 10.1002/anie.201104507. Epub 2011 Oct 26. No abstract available.

35.

Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.

Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM, Ruoslahti E.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17450-5. doi: 10.1073/pnas.1114518108. Epub 2011 Oct 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11906.

36.

Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice.

Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, Peters D, Roth L, Gagnon MK, Ferrara KW, Ruoslahti E.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7154-9. doi: 10.1073/pnas.1104540108. Epub 2011 Apr 11.

37.

Optimization of iron oxide nanoparticle detection using ultrashort echo time pulse sequences: comparison of T1, T2*, and synergistic T1- T2* contrast mechanisms.

Girard OM, Du J, Agemy L, Sugahara KN, Kotamraju VR, Ruoslahti E, Bydder GM, Mattrey RF.

Magn Reson Med. 2011 Jun;65(6):1649-60. doi: 10.1002/mrm.22755. Epub 2011 Feb 8.

38.

Nanoparticle-induced vascular blockade in human prostate cancer.

Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y, Mattrey RF, Park JH, Sailor MJ, Jimenez AI, Cativiela C, Zanuy D, Sayago FJ, Aleman C, Nussinov R, Ruoslahti E.

Blood. 2010 Oct 14;116(15):2847-56. doi: 10.1182/blood-2010-03-274258. Epub 2010 Jun 29.

39.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E.

Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.

40.

Synthetic surfaces for human embryonic stem cell culture.

Kolhar P, Kotamraju VR, Hikita ST, Clegg DO, Ruoslahti E.

J Biotechnol. 2010 Apr 1;146(3):143-6. doi: 10.1016/j.jbiotec.2010.01.016. Epub 2010 Feb 2.

PMID:
20132848
41.

Cooperative nanomaterial system to sensitize, target, and treat tumors.

Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):981-6. doi: 10.1073/pnas.0909565107. Epub 2009 Dec 28.

42.

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.

43.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. doi: 10.1073/pnas.0908201106. Epub 2009 Sep 2.

44.

Targeting atherosclerosis by using modular, multifunctional micelles.

Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9815-9. doi: 10.1073/pnas.0903369106. Epub 2009 Jun 1.

45.

Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E.

Nanomedicine. 2009 Mar;5(1):73-82. doi: 10.1016/j.nano.2008.07.007. Epub 2008 Oct 1.

46.

In vivo tumor cell targeting with "click" nanoparticles.

von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, Fogal V, Sailor MJ, Ruoslahti E, Bhatia SN.

Bioconjug Chem. 2008 Aug;19(8):1570-8. doi: 10.1021/bc800077y. Epub 2008 Jul 9.

Supplemental Content

Loading ...
Support Center